2021 Clinical Trials DEA Safety 
Cannabis Law Report
MAY 29, 2022
In May 2021, a Nature Medicine study showed the benefits of MDMA in relieving post-traumatic stress disorder. [4] 4] In April 2021, a separate study from the New England Journal of Medicine demonstrated the efficacy of psilocybin in reducing symptoms of depression. [5] Clinical Trials and Human Subject Protections.
Cannabis Law Report
JULY 9, 2021
In June 2021, similar measures were passed in Connecticut and Texas, where medical research on psilocybin is now also legal on a statewide level. Joyce Cutler, Texas the Latest State to Legalize Psychedelic Medical Research, BLOOMBERG LAW (June 23, 2021), available at [link]. Drug Enforcement Agency (“DEA”).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
FEBRUARY 28, 2022
Clinical trials are producing promising results, creating enthusiasm for commercializing and patenting psychedelics. 1025, 1026 (2021) (reporting significant improvement of PTSD symptoms following treatment with MDMA in clinical trial); see also Alec J. Yaden & Roland R. Mitchell et al., TIMES (Nov.
Veriheal
AUGUST 31, 2020
However, social and economic barriers like racial stereotypes and lack of access to care centers have historically barred Hispanic community members from seeking medical cannabis and participating in clinical trials. Supply chains are disrupted as a result, and consumers grow fearful of buying hemp.
Cannabis Law Report
JUNE 4, 2021
The legal cannabis industry is expected to exceed $40 billion in 2021 and CBD sales should reach $5 billion. However, Delta 8-THC is explicitly listed on the DEA 7370 Controlled Substance list, so it’s hard to imagine the cases ending in any other way than saying Delta 8-THC should be regulated like cannabis. . .
Canna Law Blog
NOVEMBER 6, 2021
To acknowledge its impressive safety record and potential for treating depression more effectively than existing therapies, the Food and Drug Administration designated psilocybin a breakthrough therapy in 2018 and 2019 for treating drug-resistant depression and major depressive disorder. That power is typically delegated to the DEA.
Cannabis Law Report
APRIL 13, 2022
Complementary businesses combine to create a preeminent North American platform with operations spanning 13 wellness clinics, four research sites and one bioanalytical laboratory. Hosting clinical trials for MDMA ( MAPS Public Benefit Corporation), psilocybin (the Usona Institute), LSD (MindMed) and ketamine (the University of Utah ).
Expert insights. Personalized for you.
52 
Let's personalize your content